RT Journal Article
T1 Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
A1 Blánquez-Martínez, David
A1 Díaz-Villamarín, Xando
A1 Antúnez-Rodríguez, Alba
A1 Pozo-Agundo, Ana
A1 Muñoz-Ávila, José Ignacio
A1 Martínez-González, Luis Javier
A1 Dávila-Fajardo, Cristina Lucía
K1 Myopia
K1 Pharmacogenetic
K1 Genetic polymorphism
K1 Personalized medicine
K1 Ranibizumab
K1 Anti-VEGF
K1 VEGFA
K1 CFH
K1 ARMS2
K1 Miopía
K1 Pruebas de farmacogenómica
K1 Polimorfismo genético
K1 Medicina de precisión
K1 Factores de crecimiento endotelial
K1 Factor A de crecimiento endotelial vascular
AB High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world's population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal neovascularization (CNV) in 5 to 11% of cases. Ranibizumab is a recombinant humanized monoclonal antibody fragment. It is an anti-vascular endothelial growth factor (anti-VEGF) drug used in the treatment of CNV. Many genetic polymorphisms have been associated with interindividual differences in the response to ranibizumab, but these associations were not yet assessed among patients with high myopia and CNV. We performed a retrospective study assessing the association of genetic polymorphisms with response to ranibizumab in patients with CNV secondary to high myopia (mCNV). We included genetic polymorphisms previously associated with the response to drugs used in CNV patients (bevacizumab, ranibizumab, aflibercept, and photodynamic therapy (PDT)). We also included genetic variants in the VEGFA gene. Based on our results, ARMS2 (rs10490924) and CFH (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included VEGFA genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.
PB MDPI
YR 2021
FD 2021-11-20
LK http://hdl.handle.net/10668/4001
UL http://hdl.handle.net/10668/4001
LA en
NO Blánquez-Martínez D, Díaz-Villamarín X, Antúnez-Rodríguez A, Pozo-Agundo A, Muñoz-Ávila JI, Martínez-González LJ, et al. Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients. Pharmaceutics. 2021 Nov 20;13(11):1973
DS RISalud
RD Apr 13, 2025